{
    "organizations": [],
    "uuid": "d17359f9fe6b66450777d08f079bf458ebcc393e",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-targovax-completion-of-safety-lead/brief-targovax-completion-of-safety-lead-in-and-preliminary-immune-activation-data-in-oncos-102-trial-idUSFWN1PW17X",
    "ord_in_thread": 0,
    "title": "BRIEF-Targovax: Completion Of Safety Lead-In And Preliminary Immune Activation Data In ONCOS-102 Trial",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 7 (Reuters) - TARGOVAX ASA:\n* REG-TARGOVAX ANNOUNCES COMPLETION OF SAFETY LEAD-IN AND PRELIMINARY IMMUNE ACTIVATION DATA IN ONCOS-102 TRIAL IN MESOTHELIOMA\n* ‍DSMB HAVE RECOMMENDED THAT RANDOMIZED PART OF TRIAL CAN BE INITIATED​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-02-07T14:16:00.000+02:00",
    "crawled": "2018-02-09T06:06:13.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "targovax",
        "asa",
        "announces",
        "completion",
        "safety",
        "preliminary",
        "immune",
        "activation",
        "data",
        "trial",
        "mesothelioma",
        "recommended",
        "randomized",
        "part",
        "trial",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}